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Abstract 
 
Introduction: Ketamine is a non-competitive antagonist that acts on N-methyl-D-
aspartate (NMDA) receptors in the brain and has been used as an anaesthetic agent since 
the 1960s. It has more recently become popular as a party drug due to it’s 
hallucinogenic effects, however ketamine abusers can develop significant lower urinary 
tract symptoms with associated damage to the lining of the bladder that can be difficult 
to treat and can be referred to as ketamine-induced cystitis (KIC).  
Aims: i) To explore the neurogenic effects of ketamine, ii) To analyse histological 
features of ketamine cystitis specimens, iii) To contribute to existing preliminary 
evidence urothelial cells that express cKit are absent from ketamine-cystitis specimens.  
Methods: Immunolabelling of KIC specimens was performed to study specific 
biomarkers that included nerve growth factor receptor (NGFR), nerve filament protein 
(NFP), smooth muscle actin (SMA), vimentin, and cKit. Neuronal cell lines (B104 and 
LAN-5) were used to establish in vitro bioassays to study the effects of ketamine and 
NGF on neurite outgrowth. Normal human urothelial (NHU) cells were cultured in vitro 
and treated with ketamine to assess cKit protein expression using both RT-PCR and 
western blotting.  
Results: NGFR was seen to be upregulated in both urothelium and stroma of KIC 
specimens. SMA was expressed in urothelial cells however this was not seen in 
correlation with vimentin. cKit was absent in some KIC specimens, corroborated with 
decreased protein expression in vitro, however cKit transcript was upregulated in 
ketamine treated NHU cells. Neuronal cells treated with ketamine showed an increase in 
neurite outgrowth over the control (p<0.05). 
Conclusions: Upregulation of NGFR appears to be present in KIC specimens and could 
explain painful bladder symptoms. Whether this is caused directly or indirectly by 
ketamine has yet to be established. There is an absence of cKit expressing cells in the 
urothelium from some KIC specimens which requires further investigation. 
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1. Introduction 
 
1.1 The urothelium 
The urinary bladder and associated urinary tract are lined by urothelium, an epithelium 
that is highly specialized to facilitate changes in bladder volume and provide a 
permeability barrier to urine 
(1)
. The urothelium is a transitional epithelium and displays 
a regular stratified architecture, increasing in morphological complexity and 
differentiation from basal cells, through a variable number of intermediate cells, to the 
highly differentiated superficial or umbrella cells at the luminal surface
(2)
.  
The superficial cell layer is primarily responsible for providing the permeability 
barrier
(3)
; these cells are interconnected by tight junctional complexes, which restrict 
paracellular ion transport and polarize the cell by limiting diffusion of transport proteins 
between the apical and basolateral membranes
(4)
. Superficial cells show a unique 
specialization of the apical plasma membrane, with thickened plaques of asymmetric 
unit membrane (AUM) on the luminal surface
(5)
. These plaques are composed of a 
number of component proteins, the uroplakins (UPKs)
(6)
, which can be used as 
objective markers of terminal urothelial cytodifferentiation in many species, including 
man
(7)
. AUM plays a critical role in limiting transcellular permeability as demonstrated 
by UPKIIIa deficiency in the transgenic mouse that consequently developed an 
impaired urothelial water permeability barrier in association with incomplete plaque 
formation
(8,6)
.  
Although the uroplakins play a key role in establishing the transcellular permeability 
barrier for water and possibly some other polar substances, they are not implicated in 
the formation of the tight junctional complexes that form the paracellular barrier. The 
relative tightness of tight junctional complexes is associated with the claudins, a family 
of approximately 24 proteins which form the primary seal-forming fibrils of the tight 
junction. In the urothelium, the claudins show a differentiation stage-related pattern of 
expression, with claudin 7 expressed in all but the superficial layer of the urothelium. 
Claudins 4 and 5 are expressed at the basolateral junctions of superficial cells and 
claudin 3 is restricted to the joining points at the terminal tight junction between 
adjacent superficial cells
(9)
.  
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Other differentiation biomarkers of urothelial cells have been identified such as the 
cytokeratins(CK) with superficial cells marked by expression of CK20, whereas basal 
cells are marked by expression of CK 5 and 17. In normal urothelium CK20, as a 
marker of terminal differentiation, is typically expressed in the superficial urothelial 
cells. In urothelial dysplasia however, CK20 is not restricted to the superficial but can 
be seen in all layers of the urothelium. Harnden et al showed that normal localisation of 
CK20 in biopsies from patients with newly diagnosed superficial urothelial papillomas 
(pTa) can be informative as an indicator for determining non-recurrent disease
(10,11)
.  
Preliminary observations at the Jack Birch Unit at the University of York have 
identified a rare and distinct cKit expressing urothelial cell population in normal human 
urothelium. This sub-population of cells shows a urothelial (CK+) phenotype but is 
distinct from CD45+ leucocytes and mast cells that would typically express cKit. The 
cKit-expressing cells can be located in any one of either the superficial, intermediate, or 
basal layer of the urothelium, and appear to show a pedicle that connects the cell to the 
basement membrane. Furthermore, studies of poorly differentiated urothelial carcinoma 
cell lines suggested an absence of cKit expression, the reasons for which remain 
unclear. The implications of these findings need to be expanded upon, with the need for 
further evidence to explore the possible role of cKit positive cells in the urothelium, not 
only in normal tissue, but also in disease. 
Bladder pathology 
The urothelium has been proposed to have a sensory role with the transmission of 
information such as bladder fullness between the mucosa and its underlying nerve and 
muscle tissues of the bladder being proposed
(12,13)
. Sensory afferent and efferent nerve 
processes that innervate the urothelium, and underlying tissues that include a 
suburothelial layer of myofibroblasts and the detrusor muscle are thought to be key to 
this sensory role and play a vital role in co-ordinated bladder function
(14)
. 
Myofibroblasts arise from fibroblasts that undergo differentiation into smooth muscle-
like cells
 – care should be taken when interpreting histological findings as although 
these cells can be a found in normal suburothelial tissue, upregulation may indicate 
some level of fibrosis or scarring. They are extensively linked by gap junctions, have 
close contact with nerves, and may serve as signaling intermediaries between the 
urothelium and nerve fibres
(15)
. Communication between the tissues that comprise the 
10 
 
bladder ensures the proper function of the organ and may provide a mechanism for the 
urothelium to mediate the spontaneous activity of the smooth muscle or muscle 
contraction
(16,17,18)
. As a biomarker therefore, smooth muscle actin may be useful in the 
characterisation of bladder specimens and to explore the implications of any 
observations made. 
Dysregulation of the sensory function may be important in the pathogenesis of 
dysfunctional bladder syndromes, such as interstitial cystitis(IC)
(19)
. IC is a chronic 
inflammatory disorder of the urinary bladder that manifests as urinary frequency and 
urgency with bladder pain, in the apparent absence of any infectious agent. The 
aetiology remains poorly understood, although one hypothesis is that a compromised 
urothelial barrier is a feature of the disease; whether this is due to an inherent 
dysfunction of the urothelium itself, or an indirect influence of local factors such as 
cytokines affecting urothelial differentiation and function remains uncertain
(20)
. A 
definitive treatment remains elusive
(21,22)
.  
More recognised causative factors that can induce inflammatory changes in the bladder 
include certain drugs. For example, severe cystitis has been reported in laboratory 
animals after cyclophosphamide administration
(23,24) 
and in patients receiving the drug 
as part of their treatment 
(25)
. Cyclophosphamide (CP) is a drug with a wide spectrum of 
clinical uses, and it has been proved to be effective in the treatment of cancer and 
nonmalignant disease. CP creates cross-links in DNA, resulting in strand breaks. 
However, despite preventative measures such as aggressive hydration and the use of the 
sulfhydryl-containing compound mesna 
(26)
, this drug may induce acute inflammation of 
the urinary bladder 
(27)
. Systemic injection with CP is a widely used method of inducing 
experimental chemical cystitis in mice and rats. Haemorrhagic cystitis is a common 
complication of the use of this drug in patients with cancer, and it was shown that 
acrolein is responsible for the cystitis associated with CP 
(28,29)
. Acrolein is a highly 
reactive aldehyde derived from precursors formed by the metabolism of CP in the liver 
and possibly the kidney and bladder, but the mechanism by which acrolein reaches the 
bladder is unclear
(30)
. The remainder of the urinary tract is relatively unaffected by CP, 
and its effect on the bladder has been attributed to the duration of contact with toxic 
concentrations of acrolein resulting from the urinary storage function of the 
bladder
(28,29)
.  
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Animal studies have shown increased levels of NGF, NT-3 and BDNF mRNA in rat 
bladders in response to inflammatory stimulus after chemical irritation with turpentine, 
and have demonstrated that NGF was associated with sensory changes
(31)
. In human 
studies, raised urinary NGF and prostaglandin E2 (PGE2) have been found in patients 
with interstitial cystitis and painful bladder syndrome (PBS)
(32,33,34,35)
, and one study has 
shown that chronic ketamine abusers have higher levels of serum BDNF when 
compared to healthy subjects
(36)
, although the specific implications of this have not been 
studied further. The neurotrophins are peptides that play a crucial role in the 
development of the nervous system by determining phenotype-specific neuronal 
differentiation, and targeting innervation by directing the survival, development, and 
function of neurons 
(37,38)
. Not only are neurotrophins important in neuronal function, 
but they have also been found to play an important role in tissue inflammation and 
repair. In particular, NGF has been found to be produced by several non-nervous tissue 
types including immune inflammatory cells, epithelial cells, and smooth muscle 
cells
(39,40,41)
. p75NGFR is a member of the tumour necrosis family and plays a dual role 
by transmitting both positive and negative signals that are important in cell survival and 
cell death
(42)
. Based on the apparent upregulation of NGFR in disease and after chemical 
induced damage, it remains unclear whether this suggests a regenerative response or is 
indicative of some other neurogenic response. 
The potential local and systemic effects of drugs and their metabolites excreted through 
the urinary tract thus poses interesting questions, with particular relevance to ketamine, 
a drug that appears to cause a response in the bladder that equates to cystitis. Recent 
studies have suggested that there is a correlation between regular ketamine users or 
abusers and the development of urinary symptoms such as pain, frequency, nocturia, 
urgency, and haematuria 
(43)
. On investigation patients are found to have poorly 
functioning, small capacity bladders associated with fibrosis, which can appear grossly 
inflamed at cystoscopy 
(44,45)
. Preliminary immunohistochemical observations in 
ketamine cystitis specimens showed upregulation of p75NGFR in the urothelium and 
stroma, with the presence of densely positive stromal areas that on histological analysis 
with Clinical Pathologist Dr Jens Stahlschmidt at Leeds Teaching Hospitals NHS Trust, 
appeared to resemble nerve fibres, an observation that is not seen in normal urinary tract 
tissue. As described above, chemical irritation of the bladder has been shown to cause 
increased levels of neurotrophic factors thus leading to the question of whether 
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ketamine has neurostimulatory properties either directly or indirectly, and could 
contribute to the symptoms of pain. 
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1.2 Introduction to ketamine 
 
1.2.1 History 
Ketamine is a phencyclidine derivative that was developed at the Parke-Davis 
Laboratories USA in the 1960s. It is a non-competitive antagonist that acts on N-
methyl-D-aspartate (NMDA) receptors in the brain that control synaptic plasticity and 
memory
(46,47). Ketamine creates a “dissociative anaesthesia” characterized by a 
separation between the thalamocortical and limbic systems, thus blocking sensory input 
such as pain, whilst maintaining vital reflexes such as blood pressure, pulse, and 
respiratory rate
(48)
.  
1.2.2 Medical use, pharmacokinetics, and bioavailability 
Ketamine is used in both human and veterinary anaesthesia with doses ranging from 1-
4.5mg/kg as an intravenous infusion, and also as an analgesic in chronic pain and 
palliation, with parenteral administration in the range 0.125–0.3 mg/kg/hr, or oral doses 
ranging from 50mg-1g daily
(49,50)
. Pain threshold elevation has been shown to occur at 
plasma ketamine concentrations above 160ng/ml. The pharmacokinetics of ketamine in 
analgesic doses after intravenous, intramuscular, and oral administration suggest a 
terminal half-life of 186 minutes and with a relatively short half-life this is deemed to be 
one of the benefits of ketamine. Absorption after intramuscular injection is rapid and 
has a high bioavailability at 93%, however only 17% of the oral dose is absorbed 
because of extensive first-pass metabolism in the liver
(47)
. The primary metabolic 
pathway involves hepatic N-demethylation via the cytochrome P450 system to form 
norketamine, a pharmacologically active metabolite with one-fifth to one third the 
anaesthetic potency of ketamine
(51,52)
. Norketamine is hydroxylated to form hydroxyl-
norketamine which in turn can be conjugated to more water soluble derivatives and 
excreted through the urinary tract. Faecal excretion accounts for less than five percent of 
an injected dose of ketamine
(53,54)
. 
Another potential use of ketamine is within mental health subjects. Ketamine is thought 
to have antidepressant properties, with recent studies suggesting the antidepressant 
effect through the modulation of glutamatergic signaling
(55-60)
. In major depressive 
disorder (MDD), ketamine has shown reproducible antidepressant effects within a short 
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period of time in a condition that inherently carries a long and risky period of latency 
when treated with more conventional mono-aminergic antidepressants such 
venlafaxine
(61)
. The limitations to translation of this to clinical practice in humans are 
evident by the nature of ketamine’s anaesthetic properties and its side effects thus 
making clinical trials in humans at this stage impossible, however the mechanism of 
action will potentially open new avenues to explore alternative therapies which are fast-
acting and effective. 
1.2.3 Side-effects and potential for abuse 
The main disadvantage of ketamine as an anaesthetic is the high incidence of 
hallucinations, nightmares, and other transient psychotic effects, although these can be 
reduced by concurrent administration of benzodiazepines such as diazepam or 
midazolam. For reasons that are not fully understood, children suffer less from these 
side-effects and therefore ketamine is still regularly used in paediatric anaesthesia, but 
rarely used in adult anaesthesia. Within the last 20 years however, the side effects of 
ketamine, such as hallucinations and “near death experiences”, have provoked its status 
as a recreational drug, popular amongst party-goers, and evidenced by a study looking 
at the profile of urine taken from individuals at a rave party in Taiwan that showed 
presence of ketamine in 47% of samples
(62)
. Ketamine abuse has also become more 
prevalent in the UK and goes by various different nicknames such as K, super K, 
Vitamin K, and special K, and carries a street value of approximately £21 per gram. The 
2010/11 British Crime Survey, commissioned by the Home Office, showed an increase 
in reported use of the drug among those aged 16-24, and estimated that 300 000 people 
had used ketamine at least once, a figure that has risen from an estimated 140,000 users 
in 2007, after ketamine was added to the list of drugs surveyed following the drug’s 
classification in 2006. It is currently controlled as a Class C drug under the Misuse of 
Drugs Act 1971 although there are regularly calls for re-classification of the drug into a 
higher class. 
In addition to the psychogenic side effects of ketamine, evidence suggests a correlation 
between ketamine abuse and the development of urinary symptoms and histological 
change within the bladder, the histopathological mechanism of which remains poorly 
understood. One hypothesis is that the metabolites of ketamine are excreted in the urine 
and this may produce a directly damaging effect on the urothelium
(45)
. The contact time 
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of urine containing the hydroxyl-norketamines is obviously variable between 
individuals depending on the bladder capacity and voiding frequency, and this also may 
provide an insight into the route of exposure as has been shown with other chemical 
induced cystitis such as post-cyclophosphamide treatment. Although there is much in 
the literature about clinical presentation, clinical findings and the aetiology of ketamine 
abuse 
(44,45,63-65)
,  the actual pathophysiological mechanism of urothelial damage remains 
poorly understood. Current pharmacotherapies such as anticholinergics have little 
benefit on symptoms, and although cessation of ketamine use can improve symptoms, 
in many instances the damage to the urinary tract is irreversible and may require major 
surgery. This means removing the bladder (cystectomy) with creation of a “neobladder” 
using a section of the small intestine. 
1.2.4 Histopathological features of ketamine cystitis 
To date, few groups have studied the histological features of human bladder specimens 
exposed to ketamine. Oxley et al
(66) 
have published work on human bladder specimens 
exposed to ketamine and revealed mucosal ulceration with urothelial denudation, and 
urothelial atypia that may resemble carcinoma-in-situ (CIS). High levels of p53 and 
Ki67 expression were described that supported a malignant transformation event, 
however, the absence of Cytokeratin 20 (CK20) expression was taken by the authors as 
indicative of a benign pathology even though in fact loss of expression was originally 
described as non-informative
(10)
. One can only speculate about whether CK20 was 
absent due to loss of superficial urothelium, or that ketamine had induced changes 
leading to the down regulation of CK20. This illustrates the importance of clear 
communication between surgeons and pathologists to highlight any history of ketamine 
use in order to prevent a mis-diagnosis of CIS, the management of which is very 
different to that of ketamine-induced change.  
1.2.5 In vitro studies with ketamine 
In vitro studies using cortical neurons from monkeys showed that ketamine induced 
apoptosis is associated with an increase in translocated transcription factor NF-kB, 
down-regulation of PSA-NCAM (neuronal specific marker), and upregulation of 
NMDA receptors. The authors suggest that the upregulation of NMDA receptors is vital 
in the role of ketamine–induced apoptosis, and this is based on evidence that when the 
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synthesis of NR1, a key subunit protein of the NMDA receptor, is blocked, neuronal 
cell death is reduced
(67)
.  
Takadera et al
(68) 
have shown similar evidence of NMDA receptor involvement in rat 
cortical neurons, whereby ketamine-induced cell death could be blocked using an 
agonist of the NMDA receptor. The urinary tract of rats (full thickness, including 
muscles and nerves) has been assessed and the study found evidence of NMDA receptor 
expression in the lower urogenital tract
(69)
, although the specific cell type that expressed 
NMDA receptors was not identified. This raises the question whether the damage 
induced by ketamine exposure in the urinary bladder is a consequence of apoptosis 
mediated via NMDA receptor expression in the urothelium. Recent unpublished work 
by the Jack Birch Unit at the University of York using an in vitro human urothelial cell 
model has revealed ketamine-induced cell death in urothelial cells but showed that 
urothelial cells do not express the NMDA receptor. These findings suggest that 
ketamine must be acting in an NMDA receptor independent manner, with an alternative 
and as yet poorly understood mechanism causing damage to the urinary bladder. One 
can only speculate whether it was rat urothelial cells that expressed NMDA receptors, or 
that a difference exists between the human and the rat model.
  
Braun et al
(70)
 suggested that ketamine induces apoptosis in human lymphocytes and 
neuronal cells independently of the NMDA receptor based on their findings from in 
vitro studies and the recognition that the apoptosis-inducing effect of ketamine is not 
stereospecific, thus providing further evidence that the mechanism of damage from 
ketamine in the urinary tract is independent of the NMDA receptor.   
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2. Aims  
 
In summary, ketamine abuse has been shown to lead to cystitis with long-term and 
potentially irreversible damage to the bladder. NMDA receptors have been shown not to 
be expressed by the urothelium in humans, thus requiring an alternative explanation for 
the damage seen. Preliminary observations have suggested upregulation of p75NGFR 
expression in ketamine cystitis tissue specimens, and a loss of cKit expression in the 
urothelium. Based on the hypothesis that ketamine is inducing these changes either 
directly or indirectly, the aims of this study are: 
i) To explore the neurogenic effects of ketamine, and test the hypothesis that 
NHU cells can be induced to produce neurogenic factors when exposed to 
ketamine 
 
ii) To analyse the histological features of ketamine-cystitis specimens 
compared with normal urinary tract specimens, and relate these findings to 
the hypothesis that neurogenic stimulation is a contributory factor to the 
symptoms in ketamine-cystitis 
 
 
iii) To extend preliminary observations  that a sub-population of urothelial cells 
that express cKit are potentially absent from ketamine-cystitis specimens by 
examining the expression of c-kit on ketamine-treated NHU cells cultured in 
vitro  
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3. Objectives 
 
Experimental approach   
Previous studies have used neuronal cell lines such as LAN-5 and PC12 to assess the 
response to factors such as NGF 
(71,72)
. Cell types such as differentiated adipose derived 
stem cells (ASCs), regardless of fat source, have been shown to secrete higher levels of 
NGF and BDNF than undifferentiated ASCs and cause increased neurite outgrowth in 
co-culture bioassays with dorsal root ganglia neurons
(73)
. Other studies have used 
similar bioassays with co-culture of neuronal cells, with the measurement of neurite 
outgrowth as a marker for neurogenic stimulation; elevated levels of BDNF and NGF 
were shown suggesting that these neurotrophic factors secreted from the co-culture cells 
(mesenchymal stem cells) that were stimulating neurite outgrowth
(74)
. PC12 is a cell line 
derived from a phaeochromocytoma of the rat adrenal medulla and cells terminally 
differentiate when treated with nerve growth factor
(72,75)
.  Certain neuroblastoma cell 
lines would appear therefore to provide a suitable model for measuring response to 
neurotrophin factors. Retinoic acid and cAMP are established as neuronal inducing 
agents
(76,77)
, and could feasibly be used as controlling factors for testing against other 
agents, such as ketamine. Therefore, the first objective of this study was to establish an 
in vitro cell model to study the effects of ketamine on neuronal cells, and in the second 
instance to consider a co-culture bioassay model with urothelial cells and neuronal cells 
that would aim to test the hypothesis that urothelial cells can be induced to produce 
neurotrophic factors after exposure to ketamine. 
The experimental objectives were: 
i) Use neuronal cells as a measure of potential neurogenesis to test the effects 
of a conditioned medium removed from ketamine-treated NHU cells  
 
ii) Examine both normal and ketamine-cystitis specimens to identify and 
describe the expression of specific biomarkers. These will include nerve 
growth factor receptor (NGFR), nerve filament protein (NFP), smooth 
muscle actin (SMA), vimentin, and cKit  
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iii) Culture NHU cells in vitro to study the effects of ketamine on the expression 
of cKit, and compare results with the immunohistological findings 
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4. Methodology 
 
4.1 Histology 
4.1.1 Obtaining tissue for research purposes  
Research Ethics Committee (REC) approval was obtained to remove specimens of 
bladder. All patients gave written fully informed consent for their tissues to be used for 
research. In most cases the specimens of bladder were taken at the time of cystoscopy as 
part of their investigations, having presented with urinary tract symptoms and a history 
of ketamine abuse. These samples of bladder were fixed in 10% (v/v) formalin in PBS, 
dehydrated through graded alcohols and embedded in paraffin. Normal ureter or bladder 
specimens were used as control tissue. Five micro-meter sections were cut using a 
microtome and tissue sections were de-waxed in xylene and rehydrated through graded 
alcohol to water.  
4.1.2 Immunohistochemistry 
Immunohistochemistry was performed on the tissue sections using the 
streptavidin/biotin Complex/Horseradish Peroxidase system from Dako Cytomation 
(Ely, UK. Endogenous peroxidase activity was blocked with hydrogen peroxidase for 
10 minutes before washing under running water for a further 10 minutes. Sections 
underwent an antigen retrieval process to retrieve antigens lost during primary tissue 
processing. This involved one of the following processes depending on the optimal 
conditions for that specific antigen: 1. boiled for 13 minutes in 10mM citric acid buffer, 
pH 6.0, 2. Incubated at 37
0
C for 10mins with 0.1% trypsin solution (0.1g Trypsin 
dissolved in 0.1% CaCl2 pH 7.8(w/v), 3. Combined trypsinisation followed by 
microwave in 10mM citric acid buffer pH6.0 for 13 minutes. A 10% serum from the 
host secondary antibody used was added for 5 minutes to block any non-specific 
reaction. The primary antibody was added to the slides and left to incubate at 4
0
 Celsius 
overnight (see table 1 for list of primary antibodies used). Slides were then washed, 
incubated in biotinylated secondary antibodies and a streptavidin biotin horseradish 
peroxidase complex (Dako Cytomation) and visualized using a diaminobenzidine 
substrate reaction (Sigma-Aldrich Ltd). After sections were counterstained with 
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haematoxylin, they were dehydrated and mounted in DPX (Sigma-Aldrich Ltd). Cover 
slips were applied and the slides allowed to dry. Negative and positive antibody specific 
controls were included in all experiments. Positive control specimens used same host 
antibodies, for example Cytokeratin 7 was used as a positive control for mouse 
antibodies, HNF 3α was used for goat antibodies, and laminin was used for rabbit 
antibodies. Normal human ureter specimens were used as comparison for pattern of 
immunolabelling. Slides were visualised under brightfield conditions using an Olympus 
microscope with x10, x20, x40, and x60 objectives. 
  
Antibody Clone Storage Host Titration and 
Antigen 
retrieval 
method 
Manufacturer 
NGFR 7F10 Tray 23 
Number 
494 
Mouse 1:100 MW Novocastra 
NFP 2F11 Tray 23 
Number 
546 
Mouse 1:200 MW 
(CA) 
Dako 
SMA 1A4 Tray 1 
Number 
119 
Mouse 1:4000 
Trypsin 
Sigma 
cKit Polyclonal Tray 19 
Number 
500  
Goat 1:250 
MW 
Dako 
Vimentin Monoclonal Tray 19 
Number 
502 
Rabbit 1:100 MW Sigma 
Table 1: A list of antibodies used for immunohistochemical analysis. 
MW=microwave antigen retrieval. CA=citric acid buffer.  
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4.2 Urothelial cell culture 
4.2.1 Normal human urothelial cell culture 
NHU cells were established and maintained as finite cell lines in keratinocyte serum-
free medium (KSFM), containing recombinant epidermal growth factor and bovine 
pituitary extract at the manufacturer’s recommended concentrations (Invitrogen Ltd, 
Paisley, UK). NHU cell lines were propagated in Primaria tissue culture flasks (Becton 
Dickinson, Cowley, UK), maintained at 37
0
 Celsius in a humidified atmosphere of 5% 
CO2 in air. At approximately 90% confluency, the culture medium was aspirated and 
5ml 0.1% EDTA in PBS was added for 5 minutes at 37
0
C. The EDTA was aspirated 
and replaced with 1ml trypsin versene (0.25% trypsin in PBS containing 0.02% EDTA) 
for a further 3 minutes at 37
0
C until the cells had become detached from the base of the 
flask. Trypsin activity was inhibited by addition of 1ml trypsin inhibitor (TI) with 
KSFMc (KSFM containing growth factor and bovine pituitary extract as described 
above). The cells were aspirated from the flask and pipetted into a universal tube and 
centrifuged at 1200rpm for 4 minutes. The supernatant fluid was extracted and the pellet 
of cells resuspended in KSFMc. 20µl of cell suspension was placed on a Neubauer 
haemocytometer. The slide was placed under an inverted Nikon microscope and cells in 
the outer squares of the grid were counted and then divided by four to provide a cell 
count of 1x10
4
/ml. Cells were reseeded at the desired cell density, calculated from the 
cell count after resuspension 
(78)
. Ketamine treatments were prepared by dissolving pure 
ketamine powder into media of the same type that was used to culture cells - serial 
dilutions were performed to obtain the desired ketamine concentration.  The media was 
then added to cultured cells at the desired timepoints.  
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4.3 Neuronal cell culture 
4.3.1 B104 rat neuroblastoma cell culture 
The B104 rat neuroblastoma cells were kindly donated by Dr Gareth Evans for use in 
the neuronal cell experiments. 
Cells were cultured in medium that consisted of DMEM with pyruvate, high glucose 
and glutamine (GIBCO:41966-029), and 10% foetal calf serum (FCS). Antibiotics were 
not routinely added to the culture medium. Cells were  seeded on to 25cm
2
 Primaria 
tissue culture flasks (Becton Dickinson, Cowley, UK), maintained at 37
0
 Celsius in a 
humidified atmosphere of 5% CO2 in air and passaged when approaching 90% 
confluency.  
4.3.2 Cell passaging 
Cells were passaged every 48 hours and this process followed the same steps as for the 
urothelial cells described above with exception of the different growth medium used for 
culture. Cells were counted using the Neubauer haemocytometer and seeding density for 
plating was calculated from this. 24 well plates were used and cells were seeded onto 
13mm No 1 thickness glass coverslips that had been sterilised in the oven at 160
0
C for 
at least 2 hours. 1ml of suspension with 1x10
4
 cells was added per well and added to 
this was either 10ng/ml nerve growth factor (NGF), or 50ng/ml cyclic adenosine 
monophosphate (cAMP). A no treatment control was used for comparison. The cells 
were not treated with ketamine – the reason for this was that having not worked with 
B104 cells before, it was important to establish neurite outgrowth in response to 
positive controls to ensure correct characterisation of the cell line inorder to test the 
hypothesis that they were a suitable cell line to assess neurotrophic stimulation.   
4.3.3 Fixation, permeabilisation, and fluorescent phallotoxin staining 
After 4 days the cells washed twice with pre-warmed phosphate-buffered saline, pH 7.4 
(PBS) to remove any dead cells. The cells were then fixed in 10% formalin for 20 
minutes. After washing with PBS, 0.1% Triton X-100 with 1% bovine serum albumin 
(BSA) in PBS was added for 5 minutes. Two washes with PBS followed this. Texas 
Red-X Phalloidin (Invitrogen) in methanolic stock solution was added to PBS to obtain 
a 1:10 dilution. 1% BSA was added to the staining solution to minimise non-specific 
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background staining. The staining solution was placed on the coverslips for 20 minutes 
at room temperature.  
 
4.3.4 Hoechst stain 
Cells were washed in PBS for 5 minutes and aspirated off. Hoechst 33258 (1:10000 
dilution) was added to the cells for 10 minutes at room temperature. Slides were 
mounted in N-propyl gallate antifade and left to dry in the dark. Slides were visualised 
under epifluorescent conditions using an Olympus microscope with barrier fluorescent 
filters for Texas Red and Hoechst 33258. Images were captured and transferred to 
Neuron J software (Image J plugin). 
4.3.5 Neurite measurement 
A neurite was defined as the distance from the tip of the neurite to the junction between 
the neurite base and neural body.  
4.3.6 LAN-5 neuroblastoma cells 
A contamination problem with Mycoplasma spp. affecting the B104 cells meant they 
had to be discarded and an alternative cell line had to be found. Dr Gareth Evans kindly 
donated LAN-5 human neuroblastoma cells that had been freshly isolated and I 
maintained these cells in a quarantined environment to reduce the chances of repeat 
contamination. Cells were cultured in RPMI 1640 supplemented with 10% FCS and 1% 
glutamine. Cells were maintained as described above, with passaging of cells every 3-4 
days. Cells were seeded onto 12 well glass slides at a density of 1x10
4
 per well and 
treated with one of 1µM retinoic acid, 10ng/ml NGF, or 1µM ketamine. A control with 
normal culture medium was also used. 
After 72 hours, cells were fixed, permeabilised and stained with a fluorescent 
phallotoxin and Hoechst 33258 as described above. The slides were mounted in N-
propyl gallate antifade and allowed to dry before visualisation using the Olympus 
microscope. Images were transferred to NeuronJ software and neurite lengths were 
measured. Statistical analysis was performed using tests specified in the results section. 
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4.3.7 Freezing down LAN-5 cells 
After passaging, cells were centrifuged at 1200rpm for 4 minutes. Cells were re-
suspended in a Falcon tube in the freezing mix that consisted of 10% DMSO 
(dimethylsulphoxide), 10% serum, RPMI, 1% glutamine. 1ml of each cell suspension 
was placed in a cryo vial and labelled appropriately. Vials were stored overnight at -
80
0
C before transfer to liquid nitrogen for longer term storage. 
 
4.4 RNA extraction  
RNA extraction was kindly performed by Dr Simon Baker. 10ml polypropylene tubes 
and caps (Starstedt) were incubated overnight with 0.1% diethyl pyrocarbonate (DEPC) 
to inhibit RNAase activity.  Following this, the tubes were autoclaved to destroy DEPC. 
An area of the laboratory designated solely for RNA work was prepared and cleaned. 
5ml Trizol
TM
 reagent (Invitrogen) was added to urothelial cell cultures grown in 75cm
2
 
flasks with different treatments over specified time points. The culture medium was 
removed before addition of Trizol. Cells became solubilised and the cell lysates were 
collected in the polypropylene tubes. 1ml chloroform (0.2ml/ml of Trizol) was added , 
the tubes were vortexed and then placed on ice for 5 minutes. Lysates were centrifuged 
at 12 000g for 15 minutes at 4
0
C. The upper aqueous phase containing the RNA was 
carefully removed and transferred to a new polypropylene tube. An equal volume 
isopropanol was added at ambient temperature for a period of 10 minutes to allow RNA 
precipitation. This was centrifuged at 12 000g for 10 minutes at 4
0
C. The RNA pellet 
was washed with 75% ethanol, air-dried, and resuspended in 30µl dH20. Storage of 
RNA was at -80
0
C.    
4.5 cDNA synthesis 
Isolated RNA extracts were transcribed to cDNA using the Superscript first-strand 
synthesis System
TM
 (Invitrogen). To control for DNA or polymerase chain reaction 
(PCR) product contamination, samples were incubated with DEPC-treated water to 
provide the ‘RT negative’ reaction, and replicate samples were incubated with reverse 
transcriptase to provide the ‘RT positive’ reaction.  
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4.6 Primers 
Primer pairs for PCR were designed by Felix Wezel using published sequences from 
NCBI/Ensembl and checked for specificity using databases that included Ensembl 
project genome (http://www.ensembl.org/), the NCBI Primer Blast 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/), and UCSC Genome Browser 
(http://genome.ucsc.edu/). See table 2 below for the primer sequences used. 
The primers used were specific to cKit and GAPDH genes, the sequences of which can 
be seen below in Table 2. 
Gene Forward  
5’ - 3’ 
Reverse  
5’ – 3’ 
Size 
(bp) 
NCBI 
Ensembl 
code 
Intron Control 
cKit CTTGTTGACC 
GCTCCTTGTA 
GGATGAATTT 
TTCCGACAGC 
250 ENSG000 
00157404 
No Genomic 
DNA 
GAPDH ACCCAGAAGA 
CTGTGGATGG 
TTCTAGACGG 
CAGGTCAGGT 
201 ENSG000 
00111640 
No Genomic 
DNA 
 Table 2: The above table shows the primers used for the RT-PCR experiments. 
GAPDH was used as a housekeeping gene to test cDNA integrity and act as a method 
control. 
 
4.7 Reverse transcriptase-polymerase chain reaction (RT-PCR) 
RT-PCR was performed on a PCR Express Thermal Cycler (Hybaid). 19µl of PCR 
mastermix was prepared for each cDNA sample formed from the cDNA synthesis 
described above. The PCR mastermix contained 2µl Surestart Taq Buffer (Stratagene), 
0.4µl (10mM) dNTP, 2µl (10µM) forward primer, 2µl (10µM) reverse primer, 0.1µl 
Surestart Taq Polymerase (Stratagene) and 12.5µl of DEPC-treated water. The total 
volume of mastermix was dependent on the number of cDNA samples used. 1µl of 
cDNA was added to the 19µl of mastermix to provide a total volume of 20µl. GAPDH 
was used as a housekeeping gene – this is a constitutive gene that is required for the 
maintenance of basic cellular function, is expressed in all cells of an organism, and 
acted as the method control for RT-PCR and tested cDNA integrity.  1µl of genomic 
DNA was used as a positive control in order to demonstrate successful experimental 
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methods and effective reagents. 1µl of no-template H20 was added to the mastermix as a 
negative control in order to demonstrate no contamination of product. 
The cDNA samples were denatured in the PCR Express Thermal Cycler for 5 minutes 
at 95
0
C followed by 30 cycles at 95
0
C for 30 seconds, annealing for 30 seconds at 57
0
C 
and 40 seconds at 72
0
C to allow extension. A final elongation phase of 10 minutes at 
72
0
C was followed by incubation at 4
0
C.  
The PCR products were visualised using gel electrophoresis. Agarose gel was prepared 
by boiling agarose in 1x TBE to provide a 2% agarose concentration. After cooling to 
approximately 50
0
C, 8µl GelRed (Cambridge Bioscience) was added and the product 
was allowed to cool further to form a gel. Any bubbles were removed carefully. 2µl 
loading dye (6x Blue/orange(Promega)) were added to each PCR product tube and each 
sample was loaded in to the wells. 6µl of 100bp DNA ladder (Hyperladder IV, 
Invitrogen), was run in each experiment to measure the size of DNA. The gel was 
covered in approximately 200mls 1xTBE and run at 110 Volts for 60-120 minutes. 
Once the loading dye showed a good degree of separation from the wells, the gel was 
transferred to a transilluminator with Genesnap software (Syngene) and the images were 
downloaded.  
 
4.8 Western blotting 
Protein lysates had been prepared by Dr Simon Baker at the Jack Birch Unit, University 
of York. 
Proteins were resolved by electrophoresis through NuPAGE gels using the Novex 
system(Invitrogen). The pre-cast gels and running buffers used were based upon the 
molecular weight of the target protein (145kDa), with 4-12% Bis-Tris used as the Gel 
and MOPS used as the running buffer. Combs were removed, the wells washed with 
running buffer, and the gels were assembled in the Novex tank according to 
manufacturer’s instructions. 10-20µg of each protein lysate was made up to 18µl with 
dH20 and had 4µl NuPAGE LDS, which incorporates a loading dye, added. Samples 
were incubated at 70
0
C for 10 minutes. Gels were also loaded with 5µl of Kaleidoscope 
and All-Blue prestained molecular weight markerladders (Bio-Rad). Gels were 
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electrophoresed at 125V for 60 minutes or until the dye front ran to the bottom of the 
gel. 
Total protein separated by SDS-PAGE was transferred to PVDF membranes at 30V for 
2 hours at 4
0
C using the Novex system (Invitrogen). PVDF membranes were pre-wet 
with methanol, rinsed in distilled water and then equilibrated in transfer buffer for 5 
minutes. Transfer buffer was a solution of 12mM Tris and 96mM glycine in dH20 with 
20% (v/v) methanol. The membranes were stained with ponceau red for a few seconds 
to test transfer efficiency and concentration of protein across the lanes on the 
membrane. The ponceau red stain was washed off with dH2O. 
 
Membranes were blocked using a 50% Odyssey Blocking Buffer (Li-Cor) in TBS for 1 
hour at room temperature on an orbital shaker. The membranes were probed with the 
primary antibody diluted in 50% Odyssey blocking buffer in TBS containing 0.2% 
Tween-20 overnight (for 18 hours) in the fridge at 4
0
C on an orbital shaker. The 
primary antibody used was cKit (R&D systems, polyclonal goat antibody) at 1:2000 
concentration. Negative control lanes were used alongside using the same conditions 
but without addition of the primary antibody. To achieve this, the negative control lane 
membranes were cut off and incubated in TBS separately without the primary antibody. 
The membranes underwent four five-minute washes with TBS-Tween 0.1%. 
Membranes were then probed with the secondary antibody (Alexa fluor donkey anti-
goat 1:2000 concentration) diluted in 50% Odyssey blocking buffer in TBS-Tween 
0.2% for 1 hour at room temperature on an orbital shaker and covered in foil to protect 
from light. Membranes were washed four times with TBS-Tween 0.1% and once with 
TBS for five minutes each protected from the light. Proteins were visualised by 
epifluorescent illumination at 800nm using the Odyssey system (Li-Cor). Scans were 
analysed using Odyssey software (Li-Cor), which was used to measure band intensity 
and perform background subtraction. Band intensities were measured by drawing boxes 
around the bands and using the Li-Cor Odyssey software to calculate integrated 
intensity by measuring box height, by length, by pixel intensity. Membranes were 
stripped to allow re-probing by incubation in Western Blot Recycling Kit reagent 
(Autogen Bioclear) for 30 minutes at room temperature on an orbital shaker. 
Membranes were then washed in TBS, re-blocked and re-probed as described. Negative 
control lanes were included which contained protein but no primary antibody to ensure 
there was no non-specific secondary antibody binding.  
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5. Results 
 
5.1 Immunohistochemistry 
5.1.1 Nerve Growth Factor Receptor (NGFR) 
In normal human urothelial tissue, NGFR expression was confined to the basal layer of 
the urothelium and was not typically seen in the stroma (Fig 1).  
 
 
 
 
 
  
Figure 1: image of normal human urothelium in a sample of ureter labelled with 
anti-human p75NGFR antibody. The dark brown stain in the basal layer of the 
urothelium shows NGFR expression which is normal. The stroma does not show 
NGFR expression.  
Basal layer  
urothellium 
Stroma 
       100µm 
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NGFR expression in ketamine-induced cystitis (KIC) specimens varied from the normal 
pattern, with suprabasal expansion of NGFR into the intermediate urothelium, and in 
some specimens NGFR positive cells were seen throughout the full thickness of the 
urothelium. Of the 20 KIC samples examined, only three specimens had urothelium that 
appeared intact after immunolabelling, and of these, one had full thickness urothelial 
NGFR expression, one had suprabasal expansion, and the other had a normal pattern of 
expression (Fig 4). 
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Urothelium 
Stroma 
       100µm 
 
Figure 2: This shows a sample of KIC bladder tissue labelled with anti-human 
p75NGFR antibody. It shows NGFR expression in all layers of the urothelium 
(basal, intermediate, and superficial). In normal urothelium, NGFR is confined to 
the basal urothelium, thus indicating an increase in NGFR expression in KIC tissue. 
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Figure 3: This KIC sample is labelled with anti-human p75NGFR. It shows NGFR 
expression in the basal layer of the urothelium with expansion of NGFR expression into 
the intermediate urothelial layer. NGFR is largely absent from the superficial urothelial 
cells.  
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Figure 4: This shows a further KIC bladder sample labelled with anti-human 
p75NGFR antibody. NGFR expression is localised to the basal urothelium, as is 
seen in normal urothelium. There is no evidence of suprabsal expansion in this 
sample thus indicating a normal pattern of NGFR expression. 
       100µm 
Urothelium 
Stroma 
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Seven of the remaining KIC samples showed a partially-denuded urothelium and a 
mixed pattern of NGFR expression, with three samples displaying full thickness 
expression, two samples displaying suprabasal expansion, and two samples showing a 
normal pattern of expression. The denudation of the urothelium in one sample was such 
that the superficial and intermediate layers were absent; therefore comments were only 
made upon the condition of the urothelium, and not about whether there was suprabasal 
expression.  
The normal control tissue (ureter) lacked NGFR expression in the stroma. In the KIC 
samples, 16 out of 20 of these showed stromal NGFR expression, and in 13 of the 
samples, large NGFR positive nerve fibres were seen. These were identified as a 
collection of NGFR positive cells that formed an organised structure within the stroma 
with the appearances of a nerve fibre (Fig 5) as confirmed by the clinical histo-
pathologist Dr Jens Stahlschmidt at Leeds Teaching Hospital NHS Trust. 
 
 
 
 
 
 
  
35 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: This image shows a KIC bladder sample labelled with anti-human 
p75NGFR antibody. Note the dense red/brown area within the stroma that is 
positive for NGFR. The swirly appearance of this is not seen in normal tissue 
and resembles a large nerve fibre. These observations were made with the help 
of Dr Jens Stahlschmidt, a clinical pathologist at Leeds Teaching Hospitals 
NHS Trust.  
Nerve 
bundle 
       100µm 
Absent urothelium 
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5.1.2 Nerve filament protein (NFP) 
In normal human tissue of the urinary tract, there was no evidence of NFP expression 
within either the stroma or the urothelium (Fig 6). The majority of the KIC samples 
(18/20) showed expression of NFP in the stroma, with three of these samples being 
strongly positive (Fig 7). One KIC sample showed a normal pattern of expression of 
NFP, and the other KIC sample could not be interpreted due to the quality of the 
specimen having degraded significantly at the time of biopsy.  
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Figure 6: This image shows normal human ureter labelled with neurofilament 
protein (NFP) antibody. There was no evidence of NFP in the normal tissue. 
Urothelium 
Stroma 
       100µm 
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Figure 7: This image shows a KIC sample labelled with NFP. Note the positive 
NFP expression within the stroma. This could represent nerve fibres within the 
stroma that are not seen in normal tissue. 
Unidentifiable  
urothelium 
NFP positive 
fibre 
Stroma 
       100µm 
39 
 
5.1.3 Smooth muscle actin (SMA)   
As expected in normal urothelial tissue, SMA expression was absent from the 
urothelium, as illustrated in a human ureter specimen (Fig 8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 8: This image shows normal human ureter labelled with smooth muscle 
actin (SMA). The urothelium did not express SMA. The stroma expressed SMA 
confined to smooth muscle fibres as seen. 
       100µm 
Urothelium 
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13 KIC samples displayed identifiable urothelium and of these SMA was not seen in 10, 
however the other three KIC samples showed urothelial expression. Of the three KIC 
samples that showed urothelial expression, one sample showed SMA expressed 
throughout all layers of the urothelium, one sample displayed SMA confined to the 
basal layer, and one sample showed SMA in the intermediate and superficial layers of 
the urothelium (Fig 9). No comment could be made on urothelial expression in those 7 
KIC samples that lacked identifiable urothelium.   
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Figure 9: This KIC sample showed SMA expression in the superficial 
urothelium that extended down into the the intermediate urothelial layer. As 
expected, SMA was also seen in the stroma confined to smooth muscle fibres. 
Blood vessel 
Smooth muscle 
fibres 
       100µm 
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5.1.4 Vimentin 
In normal urothelial tissue, vimentin was typically seen in the suburothelial layer (Fig 
10). Although no double labelling experiments were performed, the pattern of vimentin 
expression in the suburothelial layer appeared on observation to be similar to smooth 
muscle actin expression. Further work is obviously required to confirm this and double 
labelling could be a viable method of determining co-localisation of vimentin with 
smooth muscle actin. All KIC samples displayed vimentin positive cells in the 
suburothelial layer in keeping with a normal pattern of expression (Fig 11).  The pattern 
of vimentin did not mimic the urothelial expression of SMA seen in some KIC 
specimens.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: The image above shows normal ureter labelled with vimentin antibody. 
Expression seen as the dark red/brown cells was confined to the stroma. No 
urothelial expression was seen. 
Urothelium 
       100µm 
Stroma 
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Figure 11: This shows a KIC sample labelled with vimentin antibody. Expression 
was confined mainly to the suburothelial layer. There was no evidence of 
urothelial expression. 
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5.1.5 cKit 
In normal human urothelium, occasional cKit positive cells were seen (Fig 12).  
Five of the KIC samples showed a similar pattern to normal, with the occasional 
positive cKit cell in the urothelium. The cells were tear-shaped in structure and 
appeared in the suprabasal urothelium with a pedicle extending down towards the 
basement membrane. Six of the KIC samples showed an absence of cKit positive cells 
in the urothelium (Fig 13). The remaining nine KIC samples did not have identifiable 
urothelium to comment on the presence or absence of cKit positive cells.  
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Figure 12: The image above shows normal ureter labelled for cKit. The red cells in 
the urothelium indicated cKit expression. These cells appeared to show a pedicle 
that was attached to the basement membrane. cKit positive cells seen in the stroma 
were thought to be mast cells based on their morphological appearance 
       100µm 
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Figure 13: This shows a KIC sample labelled with cKit. The presence of cKit 
positive mast cells was seen in the stroma similarly to normal tissue. There was 
however an absence of cKit expressing cells within the urothelium. 
       100µm 
Urothelium 
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5.2 Neuronal cell culture 
5.2.1 B104 cells 
After 4 days, B104 cultures exposed to 10 ng/ml NGF or 50 ng/ml cAMP had 
significantly extended neurites compared to the no treatment control (Fig 15). The 
initial experiment appeared to demonstrate a difference in neurite outgrowth between 
treatment groups that included 10ng/ml nerve growth factor (NGF), cyclic adenosine 
monophosphate (cAMP), versus a normal culture medium control (Figs 14 & 15).  
 
 
 
 
Statistical analysis was performed using the Kruskal-Wallis test and calculated a p-
value of 0.001 (p-value<0.05 deemed to be significant). A Dunn’s post-test was 
performed to compare groups. The difference between NGF treatment and the control 
was not statistically significant with a p-value>0.05, however a statististically 
significant difference was found between cAMP treatment versus the control group, and 
NGF treatment versus cAMP treatment with p-values<0.05. However, the cultures were 
subsequently screened for Mycoplasma spp. and found to be contaminated (see Fig 16), 
therefore this cell line was discarded and an alternative neuronal cell line was identified 
to use in future experiments (LAN-5 cells). 
Figure 14: This graph shows the average neurite length for B104 cells in different 
treatment conditions. The greatest effect was seen in 50ng/ml cyclic adenosine 
monophosphate treatment (cAMP), followed by 10ng/ml nerve growth factor (NGF) 
treatment. The least neurite length was seen in the no treatment control group. 
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Figure 15: The images above show B104 cells treated with either 50ng/ml cAMP, or 
10ng/ml NGF, or no treatment (control). After 4 days the cells were fixed and stained 
with TexasRed Phalloidin and Hoechst 33258. The images at the top show 
fluorescent images for each group and there appeared to be a difference in neurite 
length between treatment groups. Analysis of multiple images using NeuronJ 
software appeared to confirm these observations. Phase contrast images can also be 
seen and appear to show differences in neurite length with the greatest effect seen in 
the cAMP treatment group. 
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  Figure 16: The fluorescent images above show B104 cells stained with Hoechst 
33258. The cells appeared to be positive for Mycoplasma spp. The cells were 
therefore discarded and an alternative neuronal cell line was selected(LAN-5 cells). 
Mycoba 
Mycoplasma 
Mycoplasma 
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5.2.2 LAN-5 cells 
An initial experiment was performed to compare the effects of 1µM retinoic acid, 
10ng/ml NGF and 1µM ketamine versus normal culture medium on LAN-5 
neuroblastoma cells. Effects were measured by length of neurites sprouting from cells. 
Retinoic acid appeared to show the greatest effect on the length of neurite extensions at 
72 hours, with NGF showing the next greatest effect, followed by ketamine (Fig 17).  
 
 
 
 
 
 
 
Although there appeared to be a difference in neurite length between treatment groups, 
this observation was only comparable between treatment groups and could not be 
validated against the control due to poor cell adherence in the control group that did not 
permit analysis of neurite length. Statistical analysis could only show a statistical 
Figure 17: This graph displays average neurite length of LAN-5 
neuroblastoma cells treated with either 1µM retinoic acid, 10ng/ml 
NGF, 1µM ketamine, or no treatment (control). Unfortunately the cells 
in the control group had poor adherence and were lost during washing. 
Amongst the treatment groups, the greatest effect on average neurite 
length was seen in retinoic acid treated cells, followed by NGF and 
then ketamine. The difference between treatment groups was found to 
be statistically significant (p<0.001). 
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difference between treatment groups and this was measured with a p value <0.001. A 
repeat experiment with the same treatment conditions showed the greatest response 
regarding neurite outgrowth in the 1µM ketamine treatment group, followed by NGF, 
retinoic acid, and the control group respectively (Fig 18). Statistical analysis was 
performed using the Kruskal-Wallis test with a p-value of 0.0015. A Dunn’s post-test 
was performed to compare groups (a p-value<0.05 was deemed to be statistically 
significant). A statistically significant difference in neurite length was identified 
between the ketamine treatment group versus the control, and NGF treatment group 
versus the control (p-value<0.05). No significant difference was identified in the other 
groups that included retinoic acid treatment group versus the control, retinoic acid 
versus ketamine, retinoic acid versus NGF, and ketamine versus NGF (p-value>0.05).     
 
 
   Figure 18: This graph displays the average neurite length of LAN-5 
neuroblastoma cells treated with either 1µM retinoic acid, 10ng/ml 
NGF, 1µM ketamine, or no treatment (control). The greatest effect was 
seen in the ketamine treated cells, followed by NGF, retinoic acid, and 
no treatment control respectively.  A statistically significant difference 
was only detected between the ketamine treated cells against the 
control, and the NGF treated cells and the control (p<0.05). 
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5.3 Western blot 
5.3.1 Western blotting for cKit 
cKit protein expression was examined in lysates prepared from cultured control NHU 
cells and following exposure to 1mM ketamine over a specified time-course. cKit 
expression was increased in both groups over the 14 day time course, with increased 
expression in the non-treated group compared to the ketamine-treated group (Fig 19).  
actin was included as a loading control.  These results indicated that treatment with 
ketamine may reduce cKit expression in NHU cells.   
 
 
  
Figure 19: This image displays a Western blot for cKit protein 
expression over a specified time-course for ketamine treated cells 
against a no-treatment control (c=control, k=ketamine). B-actin was 
used as a method control and this was present across all samples. NHU 
cells were treated with 1nM ketamine over a 14 day time-point. 
Samples were taken at day 0, day 1, day 3, day 7, and day 14. cKit 
protein expression was seen to increase in samples for both cell lines 
(ketamine treated and no treatment control) over 14 days. Greater cKit 
protein expression was seen in the control samples (1C, 3C, 7C, 14C) 
compared to the ketamine treated cells (1K, 3K, 7K, 14K).  
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5.4 RT-PCR 
5.4.1 RT-PCR for cKit  
RT-PCR was performed on NHU cell lines in two experiments using independent donor 
cell lines. cKit expression was measured in proliferating cells, cells cultured for 7 and 
14 days in normal culture medium, and cells treated with 1mM ketamine for 7 days and 
14 days. B-actin was used as a loading control, with both RT+ve and RT-ve reactions.  
In all experiments, a genomic DNA positive template control was positive, and the 
dH2O and the RT-ve controls were negative. 
The first urothelial cell line (Y1064) showed cKit transcript expression in day 7 
ketamine treated cells, and day 14 ketamine treated cells. A band was not visible in 
either the day 7 or day 14 control cells.  
The control proliferating cells in the second cell line (Y1108) did not show any 
expression of cKit transcript, but it was detected in both the day 7 and day 14 ketamine 
treated cells (Fig 20).  
    
 
 
 
Figure 20: This displays RT-PCR images for expression of transcript in two 
urothelial cell lines in vitro. The two rows at the top show cKit transcript in 
Proliferating cell (Pro), Day 7 no treatment NHUs, Day 7 1µM ketamine treated 
NHUs, Day 14 no treatment NHUs, and Day 14 1µM ketamine treated NHUs.  
GAPDH was used as a housekeeping gene to ensure integrity of the cDNA. The 
results showed expression of cKit transcript in Day 7 and Day 14 ketamine 
treated NHUs. The no treatment NHUs did not appear to express cKit transcript. 
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6 Discussion 
 
6.1 Nerve Growth Factor Receptor (NGFR) 
6.1.1 
This study demonstrated NGFR upregulation in KIC samples compared to control 
samples. Normal human urothelium displayed NGFR expression that was confined to 
the basal layer, however KIC samples showed a variation from the normal pattern, with 
NGFR expansion into the suprabasal urothelial layer and some samples displayed full 
thickness urothelial expression.  
Previous studies have shown increased expression of NGFR in the urothelium of 
patients with neuropathic bladder
 (79)
 and also in animal studies with bladders that are 
inflamed after exposure to a chemical irritant (cyclophosphamide) 
(80,81)
. It appears 
therefore that similarities exist between KIC samples and both neuropathic bladders and 
bladders exposed to chemical irritation with regard to the increased level of NGFR 
expression. The mechanism by which NGFR upregulation occurs remains unknown, 
however some of the possibilities may include: 
i) Inflammatory response from the urothelium caused by chemical irritation such 
as cyclophosphamide or ketamine  
ii) Direct inducing effects of a chemical on the urothelium to upregulate NGFR 
expression 
iii) Indirect effects whereby induced endogenous factors cause NGFR upregulation 
iv) NGFR is present as a bio-marker of tissue regeneration following injury 
 
At cystoscopy, patients with ketamine cystitis have small capacity, contracted bladders 
with erythematous and often ulcerative appearances. Ketamine and its metabolites are 
excreted via the urinary tract and may be stored in the bladder for up to several hours. 
One of the possibilities therefore, is that ketamine in contact with the urothelium has a 
directly positive and neurostimulatory effect on the expression of NGFR in urothelial 
cells. One would expect though that if this were simply the case, superficial urothelial 
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cells would show NGFR expression in a greater number of KIC samples, however 
superficial expression was not seen in the majority of KIC sample but rather the general 
pattern seen was NGFR expansion from the basal layer into the suprabasal layer of the 
urothelium. An alternative possibility to the direct contact effects of ketamine as a cause 
of increased NGFR, is that ketamine is able to induce the production of factors such as 
NGF or BDNF that bind to NGFR. Whether these factors are secreted from urothelial 
cells, stromal cells or are part of a larger systemic or circulatory ketamine response has 
yet to be determined, however one study has shown that patients with a history of 
chronic ketamine use have higher levels of serum BDNF 
(36)
, although the mechanism 
of modification in the production and utilization of BDNF remains unexplained.  
The stromal appearances in some KIC samples showed areas with dense NGFR 
expression that resembled nerve fibres. These were identified as a collection of NGFR 
positive cells that formed an organised structure within the stroma with the appearances 
of a nerve fibre as confirmed by a clinical histo-pathologist. These structures were not 
present in the control specimens and could explain why patients with a history of 
ketamine abuse develop painful bladders. Furthermore, the samples with a higher 
expression of stromal NGFR appear to have a more denuded urothelium than those with 
lower expression. This could simply be an incidental finding, or it could be significant 
that the loss of urothelium in KIC samples is a pre-disposing factor to increased stromal 
NGFR expression, and could determine severity of symptoms, although the clinical 
correlation has yet to be established. Future work will aim to address this by stratifying 
patients according to symptoms to better understand the relationship between symptoms 
severity and NGFR expression.    
The identification of NGFR in other tissues such as oral mucosa and prostatic 
epithelium
(83,84)
 suggests a role of NGFR that is integral to cells with distinct 
regenerative capacity. Urothelial tissue can be considered also as having excellent 
regenerative capacity, thus further emphasising the integral role of NGFR in 
regeneration. Other studies have demonstrated NGFR in bone marrow mesenchymal 
stem cells (MSCs) which are a population of multipotent cells that can proliferate and 
differentiate into multiple mesodermal tissues 
(82)
. The increased NGFR expression in 
KIC samples could indicate the innate response of urothelial cells with their distinct 
regenerative capacity, reacting to insult and damage induced either directly or indirectly 
56 
 
by ketamine, and demonstrating a regenerative cellular response, with NGFR acting as a 
marker of progenitor cells in the urothelium. 
6.1.2 Limitations and future work 
The significance of using ureter as a model for the study of urothelial cellular processes 
rather than bladder tissue may have certain implications. Embryological differences 
exist between these two tissues, with the ureter and bladder trigone of mesodermal 
origin, whereas the bladder and urethra are derived from the endoderm 
(85)
. Common 
procedures that have provided urothelial specimens include pyeloplasty for pelvi-
ureteric junction obstruction, ureteric re-implantation for vesico-ureteric reflux, nephro-
ureterectomy, and renal transplant surgery. The very nature of these procedures mean 
that the specimen provided is ureter rather than bladder, as there are very few 
procedures whereby a healthy bladder is removed. Normal bladder specimens are 
thereby extremely difficult to obtain for research purposes and for these experiments, 
normal ureter was used as a control. The same cellular processes are thought to occur in 
the urothelium derived from ureter as that derived from bladder, however this can not be 
verified in this study and may provide a limitation. Future work ideally would use 
normal bladder as the control. This study relied on the collection of KIC samples from 
hospitals in the UK. 20 KIC samples were included in this study. The clinical details of 
each case have yet to be stratified and correlated with the immunohistochemistry 
findings and this is an area for future work. A greater number of patients suffering with 
urinary symptoms secondary to ketamine abuse will be recruited to the study and this 
will provide more KIC samples for analysis and comparison. 
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6.2 Neurofilament protein (NFP) 
6.2.1 
Normal tissue (ureter) did not express NFP, however the majority of KIC samples 
displayed NFP in the stroma that appeared to be confined to nerve fibres, but these were 
not prolific. There was no evidence of NFP in the urothelium and thereby NFP did not 
appear to co-localise with NGFR positive urothelial cells. Three of the KIC samples 
showed large NGFR positive structures forming around NFP positive fibres. This 
suggests a neuronal response within the stroma that is consistent with the hypothesis 
that these changes are driven either directly or indirectly by ketamine. 
6.2.2 Future work 
Further work is needed to assess whether these findings correlate to the clinical 
symptoms of ketamine abuser. Serial sectioning of KIC samples would also be useful to 
look at co-localisation of nerve fibre staining antibodies. 
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6.3 cKit 
6.3.1 
This study demonstrated the absence of cKit positive cells from a number of KIC 
samples. Normal urothelium demonstrated occasional tear-shaped cKit positive cells 
with a pedicle that extended to the basement membrane. The role of cKit in the 
urothelium remains poorly understood, however the context of these findings can be 
explored.  
6.3.2 What is cKit?  
c-Kit (CD 117) is a tyrosine kinase receptor that is bound to by stem cell factor (SCF) 
that acts as a cKit ligand. c-Kit is expressed in various cell types including 
haematopoietic stem cells (HSCs), mast cells, melanocytes, and germ cells. It is also 
expressed in hematopoietic progenitor cells including erythroblasts, myeloblasts, and 
megakaryocytes. However, with the exception of mast cells, expression decreases as 
these hematopoietic cells mature and c-Kit is not present when these cells are fully 
differentiated 
(86)
. The activation of c-Kit leads to the activation of multiple signalling 
cascades, including the RAS/ERK, PI3-Kinase, and Src kinase pathways.  These are 
important pathways in cellular proliferation, differentiation and survival, and 
inappropriate activation is common in human cancers such as melanoma and sarcoma 
(87,88)
. Studies have shown that malignant melanocytes lose cKit expression during 
melanoma progression
(89)
 thus suggesting an alteration in the cKit pathway that may 
influence progression to malignant disease. 
6.3.3 cKit expression in the gastro-intestinal tract 
Previous studies have described interstitial cells of Cajal (ICC) that express cKit. ICC 
are thought to be pacemaker cells that are important in regulating neurotransmission and 
smooth muscle activity within the gastro-intestinal tract 
(90)
.  Mutations in c-kit or stem 
cell factor have been shown to result in the absence of ICC, and without these cells, 
electrical slow waves are absent and peristalsis becomes impaired.  
6.3.4 cKit expression in the urinary tract 
Animal studies have described the presence of ICC in the urothelial, suburothelial and 
muscular layers of the urinary tract 
(91,92,93)
. ICC in the suburothelial layers were found 
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to be more prevalent in rats with bladder outflow obstruction, however the study that 
included urothelium, showed a decrease in ICCs in the urothelial area and detrusor 
smooth muscle in menopausal rat urinary bladders which exhibited bladder overactivity.  
One study in humans investigated the expression of c-kit positive cells in the muscle 
layer of congenital pelvi-uretric obstruction in children and found decreased expression 
in the muscle layers compared to normal ureter
(94)
. Although there is little evidence 
from previous studies regarding the role of cKit within the urothelium, decreased 
expression in the urothelium of rat bladders with bladder overactivity could indicate a 
mechanico-sensory role of cKit expressing cells within normal urothelium, acting in a 
similar role to interstitial cells of Cajal found in the submucosal layers of both the 
urinary and gastrointestinal tract, and that can become down-regulated in disease.  
Evidence to support this in this study can be found in the immunohistochemistry 
performed on KIC samples that demonstrated the absence of cKit in the urothelium. 
Furthermore, ketamine cystitis patients often have the clinical symptoms of bladder 
overactivity with urinary frequency, urgency, and nocturia. The correlation of symptom 
severity with absence of cKit on immunohistochemistry has yet to be established and 
will provide an area for future work, with stratification of patients to the respective KIC 
specimens. The presence of cKit within the stroma was no different in the comparison 
of normal tissue with KIC samples - expression of cKit and cellular structure were 
consistent with mast cells and therefore no further inferences were made regarding cKit 
presence within the stromal layer.  
Another possible role of cKit within the urothelium is as a marker of regulation. As 
discussed previously, cKit is important in regulatory pathways that determine 
proliferation, differentiation, and survival, therefore absence of cKit could indicate a 
disruption in the normal pathways that lead to tissue damage. This could lead to an 
impaired ability for the urothelium to regenerate and this would correlate with both the 
macroscopic and microscopic appearances of the bladder in ketamine cystitis patients 
with evidence of tissue denudation. 
Western blot analysis of NHU cells treated with ketamine showed reduced cKit protein 
expression compared with the control NHUs without treatment. This in vitro experiment 
supports the theory that ketamine down-regulates cKit protein expression in NHU cells. 
However, RT-PCR performed on two NHU cell lines treated with ketamine versus the 
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normal control detected cKit transcript in both day 7 and day 14 of the ketamine treated 
cell samples. This suggests that cKit transcript expression increases in the presence of 
ketamine, but cKit protein expression is reduced as shown using the Western blot. The 
reasons for this remain unclear. One possibility is experimental differences and the first 
thing to do will be to repeat these experiments to ascertain consistent reproducibility. 
There are many processes between transcription and translation - the stability of cKIT 
protein has yet to be established and how ketamine may directly or indirectly influence 
this stability.   
 
6.3.5 Limitations and future work 
A relatively small number of KIC samples were studied (20) and correlation to the 
clinical symptoms was not possible at this stage. Future work will aim to stratify 
patients to KIC samples to identify whether symptom severity affects cKit expression. 
The results that showed increased expression of cKit transcript, but reduced cKit protein 
in ketamine treated cells provides a very interesting area for further work to explore the 
potential mechanisms that are involved.  
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6.4 Smooth muscle actin (SMA) and Vimentin 
6.4.1 Smooth muscle actin 
This study identified SMA expression in the urothelium of two KIC samples and was 
absent in normal urothelium. Submucosal SMA expression was also increased in the 
KIC samples, particularly in the stroma. The implication of SMA expression in 
urothelial cells raises questions about the cell phenotype and its role in KIC.  
SMA is predominantly expressed in smooth muscle cells, of which smooth muscle α-
actin is the predominate isoform. Cell types such as myofibroblasts usually stain for 
smooth muscle actin and the intermediate filament vimentin which is a general 
mesenchymal marker, and are found subepithelially in many mucosal surfaces such as 
the gastrointestinal and genitourinary tracts
 (95)
. One possibility is that tissue damage 
form ketamine is stimulating a regenerative response, with the appearance of 
myofibroblasts in the urothelium. To test this hypothesis, immunolabelling with 
vimentin was performed on all KIC samples but with a particular focus on the samples 
that showed urothelial SMA expression in order to support the theory that SMA positive 
cells were myofibroblasts. The implication of identifying myofibroblasts in the 
urothelium would be highly significant given the role of myofibroblasts. Their role in 
wound contraction and healing by using smooth muscle type actin-myosin complexes 
would certainly fit with the overall clinical picture of ketamine cystitis patients with 
contracted and small capacity bladders. 
6.4.2 Vimentin 
Vimentin is a type III intermediate filament (IF) protein that is expressed in 
mesenchymal cells and is often used as a marker of mesenchymally-derived cells or 
cells undergoing an epithelial-to-mesenchymal transition (EMT) during both normal 
development and metastatic progression
(96)
. Mesenchymal stem cells (MSCs) are 
multipotent stromal cells that can differentiate into a variety of cell types and exhibit 
two main characteristics that define stem cells: self-renewal and differentiation. MSCs 
can also migrate to sites of injury, inflammation, tumour, and can differentiate to form 
myofibroblasts with increased expression of SMA
(97,98)
. This study identified SMA in 
the urothelium, however these cells did not express vimentin. Uncertainty remains 
therefore over the cell phenotype of the SMA positive cells. One of the possibilities is 
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that the anti-SMA rabbit antibody was non-specific in labelling for SMA, and that the 
positive cells were artefacts.  
6.4.3 Future work 
Future work will use alternative SMA antibodies to compare the results of the 
immunolabelling. Another possibility is that SMA expressing cells are not 
myofibroblasts, but have an alternative cell phenotype that expresses SMA but not 
vimentin, and this provides an area for future work.  
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6.5 Neuronal bioassay 
6.5.1 B104 and LAN-5 neuroblastoma cells 
This study successfully established neuronal cell bio-assays with two individual types of 
neuronal cells: B104 rat neuroblastoma cells, and LAN-5 human neuroblastoma cells.  
Experimentations with B104 cells used treatments that included nerve growth factor 
(NGF), and cyclic adenosine monophosphate (cAMP), with comparison of neurite 
length against a no treatment control. Despite a statistically significant difference in 
average neurite length being identified between the cAMP treated cells and the no 
treatment control, and a significant difference being detected between the NGF 
treatment group and the cAMP treatment group, it was unfortunate that these results 
were invalid due to contamination with Mycoplasma spp.  
The LAN-5 neuroblastoma cells were used for experimentation as an alternate neuronal 
cell line. Treatments included retinoic acid, NGF, and ketamine versus a no treatment 
control. One of the experiments encountered a problem with cell adherence to the glass 
slide with loss of cells in the control sample at the time of washing. This was thought to 
be due to inadequate preparation of the slide with ethanol cleaning prior to cell seeding. 
On repeat experimentation, there were no problems with cells adherence to the glass 
slides. Loss of the control group in the first experiment meant that interpretation of data 
was limited to only being able to assess for differences between treatment groups. There 
appeared to be a difference between treatment groups, with the greatest effect on neurite 
length seen in the retinoic acid group, followed by NGF and then ketamine. The second 
experiment showed the greatest effect on neurite outgrowth in the ketamine treated 
cells, followed by NGF, retinoic acid, and the control group respectively. Retinoic acid 
and cAMP were chosen as treatment groups because of their neuronal inducing 
properties; these treatments acted as useful markers with positive agonistic behaviour 
against which ketamine and NGF could be compared 
(76,77)
. 
Previous studies have used neuronal cell lines such as LAN-5 and PC12 to assess the 
response to factors such as NGF 
(71,72)
. PC12 is a cell line derived from a 
phaeochromocytoma of the rat adrenal medulla and cells terminally differentiate when 
treated with nerve growth factor
(72,75)
. This makes PC12 cells useful as a model system 
for neuronal differentiation. For this study however, PC12 cells were not readily 
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available and therefore alternate cell lines were chosen as a means to assess whether 
these could be used as a viable model for neuronal differentiation. B104 cells appeared 
to show positive effects from NGF regarding neurite outgrowth and similar findings 
were shown in LAN-5 cells, suggesting that these cell lines could be useful model for 
neuronal differentiation. Furthermore, the potentiation of neuronal differentiation that 
was seen in this study in ketamine treated cells has also been shown in another study 
that performed neurite outgrowth assays with PC12 cells treated with ketamine
(99)
. The 
hypothesis remains that ketamine is able to stimulate a neuronal response either directly 
through the effects as seen on neuronal cell lines, or indirectly via the stimulation of the 
release of factors that could include factors such as NGF which has also been shown to 
have a positive agonistic effect on neuronal differentiation. The correlation of these 
effects, with the development of painful bladder symptoms reported by ketamine 
abusers provides an interesting area for further work. From this platform, it is 
reasonable to suggest that LAN-5 neuroblastoma cells in culture can provide a useful 
model for assessing neuronal differentiation induced by both ketamine, and NGF.  
6.5.2 Limitations and future work 
Contamination with Mycoplasma spp. was unfortunate as it prevented accurate 
interpretation of the data from the B104 cells which may have been a good model for 
assessing neuronal differentiation. To encounter this problem was however a useful 
lesson in working with cells in culture and understanding the potential pitfalls to 
laboratory work and data gathering. 
Future work will use the model described with LAN-5 neuroblastoma to establish a co-
culture system whereby conditioned medium from ketamine treated NHU cells is added 
to LAN-5 cells, with subsequent measurement of neurite outgrowth.   
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7. Conclusions 
 
Ketamine induced bladder dysfunction, or ketamine cystitis, has become a more 
recognised condition amongst urologists within the last five years and continues to 
cause significant and disabling symptoms for patients who are usually of a young age 
group. The use of ketamine as a party drug is on the increase, and it is therefore 
inevitable that more patients will present to specialists with this condition over the 
coming years, thus highlighting the need for research into the potential mechanisms by 
which damage to the urinary tract occurs. Once we have a better understanding of the 
pathophysiological mechanisms at work, we are in a better position to provide and 
develop more focussed treatments for a condition which is unresponsive to conventional 
pharmacological treatments, and can often result in the need for major surgery such as 
cystectomy.  
This study has identified the upregulation of NGFR expression in the urothelium of KIC 
samples, and the appearance of large follicle-like NGFR positive areas within the 
stroma that are likely to represent large nerve fibres. It is hypothesised that ketamine is 
either directly or indirectly stimulating NGFR upregulation in both the urothelium and 
the stroma, and that the role of NGFR is important in the pathogenesis of pain 
symptoms in ketamine cystitis as seen in other studies that have revealed NGFR 
upregulation in painful bladders after chemical irritation. The immunohistochemical 
findings in KIC samples correlate with this hypothesis, and furthermore, the neuronal 
cell bioassays have shown a neurogenic response in the presence of ketamine. The 
implication of ketamine acting as a stimulator of neurite outgrowth in neuronal cells 
supports the theory for a direct role of ketamine in a neurogenic response within the 
urinary tract. However, the potential indirect role of ketamine causing NGFR 
upregulation, and the role of urothelial cells in this mechanism has yet to be established. 
Future work will involve the now established bioassay with LAN-5 neuroblastoma cells 
to create a co-culture system whereby conditioned medium from ketamine treated 
urothelial cells in vitro is added to neuronal cells in culture to study possible neurite 
potentiation. The theory remains therefore that urothelial cells could, in the presence of 
ketamine, produce factors that are important in the upregulation of NGFR and thus the 
development of painful bladder symptoms. Alternatively, other indirect effects of 
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ketamine could be the induction of centrally produced circulatory neurotrophic factors 
in vivo, such as BDNF, and this poses further questions about possible systemic effects 
of ketamine on the urinary tract, providing an interesting area for future work. 
This study showed the absence of a sub-population of cells that expressed cKit in KIC 
specimens. The role of cKit in the urothelium remains poorly understood and the 
mechanism for the loss of these cells remains unknown, however it has been shown in 
vitro that cKit is present in ketamine treated NHU cells at the transcript level but 
becomes reduced at the level of protein expression. The mechanism by which this 
occurs will provide an area for further research. It is possible that cKit expressing cells 
in the urothelium play a role in mechanico-sensory stimulation, and that the absence of 
this cell-type could contribute to the dysfunction of the bladder and the development of 
the typical urinary symptoms seen in ketamine cystitis. 
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8. Suppliers 
 
Abcam    330 Cambridge Science Park 
    Cambridge 
    CB4 0FL 
 
AbD Serotec   Endeavour House 
    Langford Lane 
    Kidlington 
    OX5 1GE 
 
Adobe Ltd   3 Roundwood Avenue 
    Stockley Park 
    Uxbridge 
    UB11 1AY 
 
AnalaR   Unit 15 
    The Birches 
    Willard Way 
    East Grinstead 
    RH19 1XZ 
 
Becton Dickinson  The Danby Building 
    Edmund Halley Road 
    Oxford Science Park 
    OX4 4DQ 
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BDH    BDH Laboratory Supplies 
    Poole 
    BH15 1TD 
 
BioRad   BioRad Laboratories  
    BioRad House 
    Maxted Road 
    Hemel Hempstead 
    HP2 7DX 
 
CoStar Ltd   40 Portman Square 
    London 
    W1 6LT 
 
Cymbus   Units J&K 
    Eagle Close 
    Chandlers Ford 
    Hampshire 
    SO53 4NF 
 
DAKO    DAKO UK Ltd 
    Cambridge House 
    St Thomas Place 
Ely 
CB7 4EX 
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Fisher Scientific  Bishop Meadow Road 
    Loughborough 
    Leicestershire 
    LE11 5RG 
 
Hewlett-Packard  Amen Corner 
    Cain Road 
    Bracknell 
    RG12 1HN 
 
Invitrogen   3 Fountain Drive 
    Inchinnan Business Park 
    Paisley 
    PA4 9RF 
 
Leica    Balliol Business Park West 
    Benton Lane 
    Newcastle Upon Tyne 
    NE12 8EW 
 
Merck    Boulevard Industrial Park 
    Padge Road 
    Beeston 
    Nottingham 
    NG9 2JR 
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Nikon    Nikon Precision Europe 
    Stadium House 
    Alderstone Road 
    Livingston 
    EH54 7DN 
 
Novocastra   Davy Avenue  
Milton Keynes 
MK5 8LB 
 
Olympus   Olympus UK 
    Keymed House 
    Stock Road 
    Southend on Sea 
    SS2 5H 
 
Pall Corporation  Europa House 
    Havant Street 
    Portsmouth 
    PO1 3PD 
 
Progen    GH Zeal Ltd 
    8 Deer Park Road 
    Merton 
    London 
    SW19 3UU 
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RA Lamb Ltd   Unit 4  
    Park View 
    Eastbourne 
    BN23 6QE 
 
Sarstedt Ltd   68 Boston Road 
    Beaumont Leys 
    Leicester 
    LE4 1AW 
 
Scientific Laboratories Wilford Industrial Estate 
Supplies Ltd   Ruddington Lane 
    Wilford 
    Nottingham 
    NG11 7EP 
 
Sigma-Aldrich Ltd  The Old Brickyard 
    New Road 
    Gillingham 
    Dorset 
    SP8 4XT 
 
Sigma Imaging Ltd  13 Little Mundells 
    Welwyn Garden City 
    Hertfordshire 
    AL7 1EW 
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Starlab Ltd   Unit 4 
    Tanners Drive 
    Blakelands 
    Milton Keynes 
    MK14 5NA 
 
Sterilin Ltd   Parkway 
    Pen-y-fan industrial estate 
    Newport 
    NP11 3EF 
 
TOCRIS   Tocris House 
    IO Centre 
    Moorend Farm Avenue 
    Bristol 
    BS11 0QL 
 
VECTOR   3 Accent Park 
    Bakewell Road 
    Orton Southgate 
    Peterborough 
    PE2 6XS 
 
World Precision   Astonbury Farm Business Centre 
Instruments   Aston 
    Stevenage 
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